Sarepta Therapeutics Says FDA Will Not Complete Eteplirsen Review By PDUFA Date; Stock Surges

By: via Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, revealed Wednesday that the U.S. Food and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.